Document is current
Any future updates will be listed below
-
Authors
Jensen, Danny https://orcid.org/0009-0007-1150-7922
Andersen, Jesper Frank https://orcid.org/0009-0001-9140-1701
Berg, Peder https://orcid.org/0000-0002-5216-2891
Birn, Henrik https://orcid.org/0000-0003-3715-7266
Flø, Christian https://orcid.org/0000-0003-1326-7495
Frøkiær, Jørgen https://orcid.org/0000-0002-6206-8065
-
Funding
Funding for this research was provided by:
Nyreforeningen (Nyreforeningen)
Fonden til Lægevidenskabens Fremme (13-170)
Helen og Ejnar Bjørnows Fond (04-121)
Dansk Nefrologisk Selskab (Dansk Nefrologisk Selskab)
P. Carl Petersen Fond (11-034)
- License Information
-
More Information
Article History
Received: 25 March 2025
Accepted: 9 June 2025
First Online: 20 June 2025
Declarations
:
: The study was approved by the Regional Ethics Committee (Committee 1, case file 1-10-72-535-12) and conducted in accordance with the Declaration of Helsinki. Informed consent was obtained from all participants prior to inclusion.
: Not applicable.
: HB reports speaker fees and/or serving on advisory boards for Novo Nordisk, AstraZeneca, Bayer, Boehringer Ingelheim, Galapagos, GlaxoSmithKline, Alexion, Otsuka Pharmaceuticals, MSD, and Vifor Pharma; received research grants from Novo Nordisk, GlaxoSmithKline and Vifor Pharma; and serves as chairman of the Danish Society of Nephrology and the Society’s working group on the Danish CKD guidelines outside the submitted work.
